RESEARCH PAPER

Molecular Mechanisms Underlying Antimicrobial Resistance in Klebsiella pneumoniae: Current Challenges and Emerging Therapeutic Interventions

Kajal Verma[1*], Dr. Harvinder Kaur Sidhu[2]

[1*]Research Scholar, Desh Bhagat University, Mandi Gobindgarh, Punjab.
Email: Kajalv875@gmail.com
[2]Professor, Faculty of Agriculture and Life Sciences, Desh Bhagat University, Mandi Gobindgarh, Punjab.
Received: 15th Jul, 2026 | Revised: 25th Jul, 2026 | Accepted: 5th Aug, 2026 | Available Online: 12th Aug, 2026

Abstract

Antimicrobial resistance (AMR) has arisen as a paramount worldwide public health challenge of the twenty-first century, with Klebsiella pneumoniae identified as a key priority pathogen by the World Health Organization. This
opportunistic Gram-negative bacterium causes several healthcare-associated and community-acquired illnesses, such as pneumonia, urinary tract infections, bloodstream infections, liver abscesses, and sepsis. The swift emergence and spread of multidrug-resistant (MDR), extensively drug-resistant (XDR), and carbapenem-resistant K. pneumoniae (CRKP) strains have significantly diminished the efficacy of traditional antimicrobial treatments, leading to heightened morbidity, mortality, extended hospital stays, and increased healthcare expenditures globally. The exceptional adaptability of K. pneumoniae is due to various resistance mechanisms, such as the synthesis of extended-spectrum β-lactamases (ESBLs) and carbapenemases, biofilm formation, overexpression of efflux pumps, enzymatic alteration of antibiotics, diminished membrane permeability, and horizontal gene transfer via mobile genetic elements.

This review thoroughly analyzes the present state of antibiotic resistance in K. pneumoniae, emphasizing the molecular and genetic processes behind its resistance phenotype and global epidemiological patterns. The review additionally addresses current therapeutic problems and assesses novel techniques designed to alleviate K. pneumoniae infections. These efforts encompass the creation of innovative antibiotics, antimicrobial peptides, bacteriophage therapy, immunotherapeutic methods, nanoparticle-based antimicrobial systems, CRISPR-Cas gene-editing technologies, anti-biofilm agents, and antimicrobial stewardship initiatives. The amalgamation of novel therapeutic strategies with efficient infection prevention, surveillance, and antibiotic stewardship initiatives may yield enduring solutions to mitigate the proliferation of resistant K. pneumoniae strains. Ongoing research and interdisciplinary collaboration are crucial for devising effective strategies to address this progressively resistant pathogen and mitigate the worldwide impact of antimicrobial resistance (AMR).

Keywords: *Klebsiella pneumoniae; antimicrobial resistance; multidrug-resistant bacteria; carbapenem resistance; biofilm formation; bacteriophage therapy; antimicrobial peptides; CRISPR-Cas; infection control; therapeutic strategies*

How to cite this article: Kajal Verma1* Dr. Harvinder Kaur Sidhu2. Molecular Mechanisms Underlying Antimicrobial Resistance in Klebsiella pneumoniae: Current Challenges and Emerging Therapeutic Interventions. Int J Drug Deliv Technol. 2026;16(78s):807-823. DOI: 10.25258/ijddt.16.78s.96.

Introduction

Antimicrobial resistance (AMR) has arisen as a critical global public health issue of the twenty-first century, jeopardizing decades of advancements made through the discovery and application of antibiotics. The swift development and spread of resistant microbes have markedly diminished the efficacy of existing antimicrobial medicines, resulting in heightened morbidity, death, extended hospitalizations, and rising healthcare costs globally. Recent global estimates indicate that antimicrobial- resistant bacterial infections directly caused over 1.27 million fatalities and were related with approximately 5 million deaths worldwide in 2019, highlighting the severity of this escalating epidemic. The World Health Organization (WHO) has

consistently recognized antimicrobial resistance (AMR) as one of the foremost global health challenges, requiring immediate scientific, clinical, and policy responses.

Klebsiella pneumoniae is a significant priority pathogen contributing to the AMR burden, noted for its exceptional capacity to acquire and spread resistance determinants. *K. pneumoniae* is a Gram- negative, encapsulated, opportunistic bacterium within the Enterobacteriaceae family. It frequently inhabits the human gastrointestinal system and nasopharynx but can induce serious infections when host immunity is impaired. The pathogen is commonly linked to hospital-acquired and healthcare-associated infections, such as pneumonia, urinary tract infections, bloodstream infections, wound infections, liver abscesses, meningitis, and septicemia. Patients in intensive care units (ICUs), those undergoing invasive medical operations, transplant recipients, cancer patients, and immunocompromised individuals are more vulnerable to infections caused by K. pneumoniae. In the last twenty years, the epidemiology of *K. pneumoniae* infections has significantly changed due to the rise of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug- resistant (PDR) strains. The rising incidence of carbapenem-resistant K. pneumoniae (CRKP) is particularly alarming, as it has emerged as a significant contributor to healthcare-associated outbreaks globally. Carbapenems have historically functioned as the final line of defense against severe Gram-negative bacterial infections; however, the extensive appearance of carbapenemase-producing strains has significantly undermined their efficacy. The propagation of carbapenemase genes, including blaKPC, blaNDM, blaOXA-48, blaVIM, and blaIMP, via plasmids and other mobile genetic elements has expedited the worldwide transmission of resistance, posing significant problems for infection management and control.

The efficacy of K. pneumoniae as a multidrug- resistant pathogen is mostly due to its remarkable genetic flexibility and varied resistance mechanisms. These methods encompass the synthesis of extended-spectrum β-lactamases (ESBLs), carbapenems, heightened expression of efflux pumps, enzymatic alteration of antimicrobial drugs, diminished outer membrane permeability via porin modifications, and the development of protective biofilms. Biofilm development notably increases bacterial persistence on medical devices and host tissues, substantially diminishing antibiotic penetration and fostering chronic infection. Moreover, horizontal gene transfer facilitated by plasmids, transposons, integrons, and bacteriophages enables the swift acquisition and spread of resistance genes throughout bacterial populations, exacerbating the global AMR epidemic.

The rise of hypervirulent K. pneumoniae (hvKP) strains, with antibiotic resistance, has heightened worries. These strains exhibit augmented virulence characteristics, including as hyper capsule synthesis, siderophore-mediated iron acquisition mechanisms, and heightened mucoviscosity, allowing them to induce severe invasive infections in otherwise healthy persons. Recent findings detailing the convergence of hypervirulence and antibiotic resistance have heightened apprehensions about the future therapeutic management of K. pneumoniae infections. These strains pose a significant danger due to their increased pathogenicity and restricted treatment alternatives.

Contemporary therapeutic approaches for resistant K. pneumoniae infections predominantly utilize combination antibiotic regimens, encompassing polymyxins, tigecycline, aminoglycosides, fosfomycin, and novel β-lactam/β-lactamase inhibitor combos. The ongoing development of

resistance mechanisms has reduced the effectiveness
of numerous traditional therapeutic strategies. The rate of novel antibiotic development has not matched the rise of resistant bacterial strains, underscoring the critical necessity for creative therapeutic alternatives and thorough infection- control strategies.

Recent advancements in microbiology, molecular biology, nanotechnology, immunology, and genetic engineering have yielded potential strategies for addressing antimicrobial-resistant K. pneumoniae. Innovative strategies including antimicrobial peptides, bacteriophage therapy, nanoparticle-based antimicrobial systems, immunotherapeutic interventions, anti-biofilm agents, quorum-sensing inhibitors, CRISPR-Cas gene-editing technologies, and novel antimicrobial compounds are currently under investigation as potential solutions to combat resistance. Concurrently, antimicrobial stewardship programs, surveillance systems, infection prevention strategies, and public health initiatives are vital elements of a holistic approach to curtail the dissemination of resistant microorganisms.

Due to the rising global challenge of antimicrobial- resistant K. pneumoniae and the restricted efficacy
of current treatment modalities, a thorough comprehension of resistance mechanisms and novel therapeutic strategies is necessary. This review seeks to assess the current state of antimicrobial resistance in K. pneumoniae, analyze the molecular and genetic mechanisms contributing to resistance development, evaluate recent advancements in therapeutic and preventive measures, and delineate future strategies for addressing this increasingly significant pathogen. This review aims to synthesize current information to inform the development of effective interventions and enhance clinical
outcomes in combating antibiotic resistance.

Mechanisms of Antimicrobial Resistance in *Klebsiella pneumoniae*

The remarkable ability of *Klebsiella pneumoniae* to acquire, maintain, and disseminate antimicrobial resistance determinants has transformed this opportunistic pathogen into one of the most challenging microorganisms encountered in modern clinical practice. The increasing prevalence of multidrug-resistant (MDR), extensively drug- resistant (XDR), and carbapenem-resistant *K. pneumoniae* (CRKP) strains is largely attributed to a combination of intrinsic and acquired resistance mechanisms. These mechanisms not only reduce the efficacy of conventional antimicrobial agents but also facilitate the rapid evolution and global dissemination of resistant clones. Understanding the molecular basis of these resistance mechanisms is essential for the development of effective therapeutic and preventive strategies.

Fig.1 Mechanisms of Antimicrobial Resistance in Klebsiella Pneumoniae



Table 1. Major Antimicrobial Resistance Mechanisms in Klebsiella pneumoniae

Resistance Mechanism	Major Genes	Antibiotic Classes Affected	Clinical Impact
Biofilm Formation	luxS, mrkA, mrkD, fimH	Multiple classes	Chronic and recurrent infections
ESBL Production	blaTEM, blaSHV, blaCTX-M	Penicillins, Cephalosporins	Treatment failure
Carbapenemase Production	blaKPC, blaNDM, blaOXA-48, blaVIM, blaIMP	Carbapenems	High mortality risk
Efflux Pumps	AcrAB-TolC, OqxAB	Fluoroquinolones, Tigecycline	Multidrug resistance
Porin Loss	OmpK35, OmpK36	β-lactams, Carbapenems	Reduced drug entry
Aminoglycoside Modification	AAC, APH, ANT	Aminoglycosides	Loss of antibiotic activity

Biofilm Formation

Biofilm formation represents one of the most important virulence-associated resistance mechanisms in *K. pneumoniae*. Biofilms are structured microbial communities enclosed within a self-produced extracellular polymeric matrix composed of polysaccharides, proteins, lipids, and extracellular DNA. These structures enable bacterial cells to adhere firmly to biotic and abiotic surfaces, including host tissues, urinary catheters, endotracheal tubes, prosthetic implants, and other medical devices.

The biofilm matrix acts as a physical barrier that limits the penetration of antimicrobial agents and protects bacterial cells from host immune responses. Within biofilms, bacterial cells exhibit altered metabolic activity, reduced growth rates, and enhanced expression of resistance-associated genes, all of which contribute to increased tolerance toward antibiotics. Studies have demonstrated that bacteria embedded within biofilms can exhibit resistance levels up to 1,000 times greater than their planktonic counterparts.

Several genes have been implicated in biofilm formation in *K. pneumoniae*, including *luxS*, *mrkA*, *mrkD*, *fimH*, *ompK36*, and *ramA*. These genes regulate fimbrial adhesion, quorum sensing, and extracellular matrix production, thereby facilitating biofilm development and persistence. Biofilm-associated infections are particularly difficult to eradicate and frequently result in chronic and recurrent infections.

Production of β-Lactamases

The production of β-lactamases is the most prevalent resistance mechanism in *K. pneumoniae*. β- Lactamases are enzymes capable of hydrolyzing theβ-lactam ring present in penicillins, cephalosporins, monobactams, and carbapenems, thereby rendering these antibiotics ineffective.

Among the most clinically important β-lactamases are extended-spectrum β-lactamases (ESBLs), including TEM, SHV, and CTX-M variants. These enzymes confer resistance to third- and fourth- generation cephalosporins and are widely distributed among clinical isolates worldwide. The rapid spread of ESBL-producing *K. pneumoniae* has

significantly reduced the utility of cephalosporins in treating severe infections.

Carbapenem resistance is primarily mediated through the production of carbapenemases. Major carbapenemases identified in *K. pneumoniae* include:

- Klebsiella pneumoniae carbapenemase (KPC)
- New Delhi metallo-β-lactamase (NDM)
- Verona integron-encoded metallo-β- lactamase (VIM)
- Imipenemase (IMP)
- Oxacillinase-48 (OXA-48)

These enzymes can hydrolyze nearly all β-lactam antibiotics, including carbapenems, which are often considered antibiotics of last resort. The genes encoding these enzymes are commonly located on plasmids, facilitating rapid horizontal gene transfer among bacterial populations.

Enzymatic Modification of Antibiotics

Another significant resistance mechanism involves enzymatic modification or inactivation of antimicrobial agents. *K. pneumoniae* produces a variety of modifying enzymes capable of chemically altering antibiotic molecules before they reach their cellular targets.

Resistance to aminoglycosides is commonly mediated through aminoglycoside-modifying enzymes (AMEs), including:

- Aminoglycoside acetyltransferases (AACs)
- Aminoglycoside phosphotransferases (APHs)
- Aminoglycoside nucleotidyltransferases (ANTs)

These enzymes catalyze acetylation, phosphorylation, or adenylation reactions that prevent aminoglycosides from binding to bacterial ribosomes. Additionally, 16S rRNA methyltransferases such as ArmA, RmtB, and RmtC modify ribosomal target sites, resulting in high-level resistance to multiple aminoglycosides.

Because the genes encoding these enzymes are often located on transferable plasmids, their dissemination contributes significantly to the global emergence of multidrug-resistant strains.

Efflux Pump-Mediated Resistance

Efflux pumps are membrane-associated transport proteins that actively expel antimicrobial agents from bacterial cells. By reducing intracellular antibiotic concentrations below therapeutic levels, these systems significantly diminish drug efficacy.

In *K. pneumoniae*, the AcrAB–TolC and OqxAB efflux systems are among the most extensively studied multidrug efflux pumps. These pumps confer resistance against numerous antimicrobial classes, including:

- Fluoroquinolones
- Tetracyclines
- Chloramphenicol
- Macrolides
- Tigecycline
- Certain β-lactam antibiotics

Mutations in regulatory genes such as *acrR* and *ramR* often result in overexpression of efflux systems, contributing to multidrug resistance. Efflux pumps also play a role in biofilm formation and

bacterial virulence, further complicating treatment outcomes.

Reduced Outer Membrane Permeability

The outer membrane of Gram-negative bacteria functions as a selective permeability barrier that regulates the influx of nutrients and antimicrobial agents. Porin proteins embedded within the outer membrane facilitate the passive diffusion of small hydrophilic molecules into bacterial cells.

In *K. pneumoniae*, OmpK35 and OmpK36 are the principal porins responsible for antibiotic entry. Mutations, deletions, or reduced expression of these porins substantially decrease membrane permeability and restrict antibiotic penetration.

Porin loss is frequently observed in carbapenem- resistant isolates and often acts synergistically withβ-lactamase production to generate high-level resistance. Reduced permeability has been associated with resistance to:

- Carbapenems
- Cephalosporins
- Fluoroquinolones
- Aminoglycosides
- Chloramphenicol

Consequently, alterations in membrane permeability constitute a critical adaptive mechanism that enhances bacterial survival under antimicrobial pressure.

Horizontal Gene Transfer and Mobile Genetic Elements

Beyond individual resistance mechanisms, the rapid dissemination of antimicrobial resistance in *K. pneumoniae* is strongly facilitated by horizontal gene transfer. Resistance genes are frequently carried on plasmids, transposons, integrons, and bacteriophages that can move between bacterial species.

Mobile genetic elements carrying carbapenemase genes such as *blaKPC*, *blaNDM*, and *blaOXA-48* have been widely reported in healthcare settings across the globe. This genetic mobility accelerates the emergence of novel resistance profiles and contributes significantly to hospital outbreaks and international dissemination of resistant clones.

Collectively, biofilm formation, β-lactamase production, enzymatic antibiotic modification, efflux pump activity, reduced membrane permeability, and horizontal gene transfer constitute the principal mechanisms underlying antimicrobial resistance in *K. pneumoniae*. These interconnected mechanisms enable the pathogen to survive exposure to multiple classes of antibiotics and represent major obstacles to effective clinical management.

3. Global Epidemiology of Antimicrobial Resistance in *Klebsiella pneumoniae*

The global emergence and dissemination of antimicrobial-resistant *Klebsiella*



decades, *K. pneumoniae* has evolved from a common opportunistic pathogen into a major multidrug-resistant (MDR) organism responsible for severe healthcare-associated and community- acquired infections. The increasing prevalence of extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant *K. pneumoniae* (CRKP) strains has substantially complicated treatment strategies and contributed to increased morbidity, mortality, and healthcare costs worldwide.

K. pneumoniae is among the priority pathogens identified by the World Health Organization (WHO) due to its high capacity for acquiring and disseminating antimicrobial resistance genes. The pathogen is frequently associated with pneumonia, bloodstream infections, urinary tract infections, surgical site infections, liver abscesses, and ventilator-associated infections. Its remarkable genetic plasticity enables the rapid acquisition of resistance determinants through plasmids, transposons, integrons, and other mobile genetic elements, facilitating the emergence of highly resistant clones.

The epidemiology of antimicrobial-resistant *K. pneumoniae* varies considerably across geographic regions. In North America, carbapenem-resistant strains emerged predominantly through the dissemination of Klebsiella pneumoniae carbapenemase (KPC)-producing isolates. Since the first identification of KPC-producing strains in the United States, these organisms have spread extensively across healthcare facilities and have become a major cause of hospital-acquired infections. Similar epidemiological patterns have been observed in several European countries, particularly Greece, Italy, and Spain, where carbapenem-resistant *K. pneumoniae* has reached endemic levels in certain healthcare settings.

Asia represents one of the most severely affected regions. China and India have reported a rapid increase in carbapenem-resistant isolates over the past decade. The widespread dissemination of New Delhi metallo-β-lactamase (NDM)-producing strains has contributed significantly to resistance rates in South and Southeast Asia. In China, surveillance studies have demonstrated a substantial rise in carbapenem resistance among clinical *K. pneumoniae* isolates, particularly in intensive care units (ICUs), where antibiotic pressure is high and vulnerable patient populations facilitate transmission. Similarly, India has become a major reservoir of NDM-producing Enterobacterales, contributing to the international spread of resistance through travel and healthcare-associated transmission.

Table 2. Global Distribution of Major Carbapenemase Genes

Carbapenemase	First Reported	Major Regions
KPC	USA	North America, Europe, China
NDM	India	Asia, Middle East, Europe
OXA-48	Turkey	Europe, North Africa, Middle East
VIM	Greece	Europe
IMP	Japan	Asia-Pacific

In Europe, antimicrobial resistance surveillance programs have documented increasing prevalence of ESBL-producing and carbapenem-resistant *K. pneumoniae*. Countries such as Greece and Italy consistently report some of the highest carbapenem resistance rates globally. The spread of epidemic clones, particularly sequence types ST258, ST11, ST147, and ST15, has played a critical role in

regional outbreaks. These high-risk clones possess a combination of antimicrobial resistance determinants and virulence factors that enhance their ability to persist and spread within healthcare environments.

The epidemiological situation in Africa and Latin America is also becoming increasingly concerning. Although surveillance data remain limited in several countries, available reports indicate a growing burden of ESBL-producing and carbapenem- resistant *K. pneumoniae*. Inadequate infection- control practices, unrestricted antibiotic access, and limited antimicrobial stewardship programs contribute to the emergence and dissemination of resistant strains in these regions. The lack of comprehensive surveillance systems may further underestimate the true burden of resistance.

A particularly alarming trend is the emergence of hypervirulent and multidrug-resistant *K. pneumoniae* strains. Traditionally, hypervirulent strains and antimicrobial-resistant strains represented separate populations. However, recent reports have documented the convergence of hypervirulence and multidrug resistance, resulting in highly pathogenic strains capable of causing severe invasive infections while simultaneously exhibiting resistance to multiple antibiotic classes. These strains represent a significant threat to global public health because they combine enhanced transmissibility, increased virulence, and limited treatment options.

Healthcare-associated transmission remains the primary driver of resistant *K. pneumoniae* dissemination. Intensive care units, long-term care facilities, transplant centers, and oncology wards are recognized as major reservoirs for resistant strains. Risk factors associated with infection include prolonged hospitalization, invasive medical procedures, mechanical ventilation, prior antibiotic exposure, immunosuppression, and the presence of chronic comorbidities. Environmental contamination and asymptomatic colonization among healthcare workers and patients further facilitate transmission.

The global epidemiology of antimicrobial-resistant *K. pneumoniae* highlights the urgent need for coordinated international surveillance, antimicrobial stewardship, infection-prevention strategies, and investment in novel therapeutic approaches. Continuous monitoring of resistance trends and molecular epidemiology is essential to identify emerging high-risk clones and guide evidence-based interventions. Without effective containment measures, the continued spread of multidrug- resistant and carbapenem-resistant *K. pneumoniae* may significantly undermine the effectiveness of existing antimicrobial therapies and pose a substantial threat to public health worldwide.

4. Current Therapeutic Options

The treatment of antimicrobial-resistant *Klebsiella pneumoniae* infections remains a major clinical challenge due to the increasing prevalence of multidrug-resistant (MDR), extensively drug- resistant (XDR), and carbapenem-resistant *K. pneumoniae* (CRKP) strains. Traditionally, carbapenems such as meropenem, imipenem, and ertapenem have been considered the cornerstone of therapy for severe infections caused by ESBL- producing isolates. However, the rapid emergence of carbapenemase-producing strains has significantly reduced the effectiveness of these agents, necessitating the use of alternative therapeutic approaches.

Currently, polymyxins (colistin and polymyxin B), tigecycline, fosfomycin, and aminoglycosides constitute the primary treatment options for CRKP infections. Polymyxins exhibit potent activity

against many carbapenem-resistant isolates; however, their clinical use is often limited by nephrotoxicity and neurotoxicity. Tigecycline has demonstrated broad-spectrum activity against MDR pathogens and is frequently used in combination regimens, particularly for complicated intra-abdominal and soft-tissue infections. Similarly, fosfomycin has gained attention because of its unique mechanism of action and synergistic effects when combined with other antimicrobial agents.

Table 3. Current Therapeutic Options Against Resistant Klebsiella pneumoniae

Antibiotic	Target Strains	Advantages	Limitations
Colistin	CRKP	Potent activity	Nephrotoxicity
Tigecycline	MDR-KP	Broad spectrum	Low serum concentration
Fosfomycin	MDR-KP	Combination therapy	Rapid resistance
Ceftazidime-Avibactam	KPC producers	High efficacy	Emerging resistance
Meropenem-Vaborbactam	KPC producers	Improved survival	Cost
Cefiderocol	CRKP	Novel mechanism	Limited clinical data

Recent advances in antimicrobial development have introduced novel β-lactam/β-lactamase inhibitor combinations, including ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam. These agents have shown promising efficacy against carbapenemase-producing *K. pneumoniae*, particularly KPC-producing strains, and have significantly improved clinical outcomes. Cefiderocol, a novel siderophore cephalosporin, has also emerged as an effective therapeutic option because it utilizes bacterial iron transport systems to gain intracellular access while maintaining stability against many β-lactamases.

Despite these advances, monotherapy often remains insufficient for severe infections. Consequently, combination therapy involving polymyxins, tigecycline, fosfomycin, aminoglycosides, or newerβ-lactam/β-lactamase inhibitors is frequently recommended to enhance bactericidal activity, reduce treatment failure, and limit the emergence of additional resistance. Nevertheless, the continuous evolution of resistance mechanisms underscores the urgent need for innovative therapeutic strategies and the prudent use of existing antimicrobial agents.

5. Emerging Therapeutic Strategies

The continuous emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and carbapenem-resistant *Klebsiella pneumoniae* (CRKP) has significantly reduced the effectiveness of conventional antimicrobial therapies. Consequently, considerable research efforts have been directed toward the development of innovative therapeutic approaches capable of overcoming resistance mechanisms while minimizing the risk of further resistance development. Recent advances in molecular biology, immunology, nanotechnology, and genetic engineering have generated several promising alternatives to traditional antibiotic therapy. Figure 3 summarizes the major emerging therapeutic strategies currently under investigation for the management of antimicrobial-resistant *K. pneumoniae* infections.

5.1 Novel Antibiotics

The discovery and development of novel antimicrobial agents remain critical for combating resistant *K. pneumoniae*. Several recently approved antibiotics have demonstrated improved activity against carbapenem-resistant and ESBL-producing strains. Novel β-lactam/β-lactamase inhibitor combinations such as ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-

relebactam effectively inhibit various carbapenemases and restore susceptibility in resistant isolates.

Another promising development is cefiderocol, a siderophore cephalosporin that exploits bacterial iron uptake systems to gain entry into bacterial cells. This unique "Trojan horse" mechanism allows cefiderocol to overcome porin-related resistance and maintain activity against numerous carbapenem-resistant pathogens. In addition, advances in bacterial genomics and computational drug discovery have facilitated the identification of novel molecular targets involved in bacterial metabolism, virulence regulation, and resistance pathways. These innovations may accelerate the development of next- generation antibiotics capable of addressing current therapeutic limitations.

5.2 Antimicrobial Peptides

Antimicrobial peptides (AMPs) are naturally occurring components of innate immunity found in humans, animals, plants, and microorganisms. These peptides possess broad-spectrum antimicrobial activity against Gram-positive bacteria, Gram- negative bacteria, fungi, and viruses. Unlike conventional antibiotics that target specific metabolic pathways, AMPs primarily disrupt bacterial membranes, causing rapid cell death.

Several studies have demonstrated potent activity of AMPs against MDR *K. pneumoniae*, including strains resistant to carbapenems and polymyxins. Furthermore, AMPs exhibit immunomodulatory properties that enhance host defense mechanisms and promote pathogen clearance. Their multifaceted mechanisms of action significantly reduce the likelihood of resistance development. Despite these advantages, challenges such as proteolytic instability, cytotoxicity, short half-life, and high production costs currently limit widespread clinical application. Ongoing research focuses on peptide engineering and nanoformulations to improve stability, efficacy, and safety.

5.3 Bacteriophage Therapy

Bacteriophages are viruses that specifically infect bacterial cells and have re-emerged as a promising alternative to conventional antibiotics. Phage therapy offers several advantages, including high specificity, self-amplification at infection sites, and minimal disruption of the normal microbiota.

Phages target *K. pneumoniae* by binding to surface receptors, injecting genetic material, and ultimately lysing bacterial cells. Certain bacteriophages also produce depolymerase enzymes capable of degrading bacterial capsules and biofilms, thereby enhancing bacterial susceptibility to immune responses and antimicrobial agents. Experimental studies have demonstrated significant reductions in bacterial burden and improved survival in animal models of CRKP infection. Although phage therapy remains largely experimental, increasing clinical evidence suggests considerable potential for managing refractory MDR infections.

5.4 Immunotherapy

Immunotherapeutic approaches seek to strengthen host defenses against *K. pneumoniae* rather than directly targeting bacterial cells. Vaccines, monoclonal antibodies, and immune-modulating agents represent the principal immunotherapeutic strategies currently under investigation.

Vaccine development has focused on capsular polysaccharides, lipopolysaccharides, outer membrane proteins, and outer membrane vesicles. These antigens stimulate both humoral and cellular immune responses capable of preventing infection and reducing bacterial colonization. Monoclonal antibodies targeting virulence factors may neutralize bacterial pathogenicity and facilitate immune-

mediated clearance. Immunotherapy is particularly attractive because it exerts minimal selective pressure for resistance development and may provide long-term protection against recurrent infections.

5.5 Nanotechnology-Based Therapeutics

Nanotechnology has emerged as a rapidly expanding field in antimicrobial research due to its ability to improve drug delivery, enhance antimicrobial efficacy, and overcome resistance mechanisms. Various nanomaterials, including silver nanoparticles, zinc oxide nanoparticles, polymeric nanoparticles, and liposomal drug delivery systems, have demonstrated significant antibacterial activity against *K. pneumoniae*.

Nanoparticles exert antimicrobial effects through multiple mechanisms, including disruption of bacterial membranes, generation of reactive oxygen species (ROS), interference with cellular metabolism, and enhanced antibiotic penetration into biofilms. Nanocarrier systems also improve drug bioavailability and enable targeted delivery, reducing systemic toxicity. The integration of nanotechnology with conventional antibiotics may provide a powerful strategy for treating highly resistant infections.

5.6 CRISPR-Cas Gene Editing Technologies

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems have revolutionized microbial genetic engineering and offer unprecedented opportunities for combating antimicrobial resistance. CRISPR-based technologies can selectively target and eliminate resistance genes, virulence determinants, or resistance-carrying plasmids within bacterial populations.

In *K. pneumoniae*, CRISPR-Cas systems have demonstrated the ability to remove carbapenemase genes such as *blaKPC* and *blaNDM*, thereby restoring susceptibility to antibiotics. This highly specific approach minimizes off-target effects and preserves beneficial microbial communities. Despite its promise, several challenges remain, including efficient delivery systems, bacterial uptake, and regulatory considerations.

5.7 Anti-Biofilm Strategies

Biofilm formation is a major contributor to persistent and recurrent *K. pneumoniae* infections. Consequently, anti-biofilm therapies have gained considerable attention as adjunctive treatment approaches. These strategies include enzymatic biofilm degradation, quorum-sensing inhibition, surface modification of medical devices, and biofilm-targeted nanoparticles.

Quorum-sensing inhibitors interfere with bacterial communication systems responsible for coordinating biofilm formation and virulence expression. Enzymes such as DNases and polysaccharide-degrading agents disrupt the biofilm matrix, enhancing antibiotic penetration and bacterial eradication. Anti-biofilm approaches may significantly improve treatment outcomes when combined with conventional antimicrobial therapy.

5.8 Host-Directed Therapies

Host-directed therapies (HDTs) represent an innovative approach that focuses on modulating host immune pathways rather than directly targeting bacterial pathogens. These therapies enhance innate and adaptive immune responses, promote bacterial clearance, and reduce tissue damage caused by excessive inflammation.

Potential HDT strategies include cytokine modulation, immunometabolic interventions, macrophage activation, and enhancement of epithelial barrier function. Because these approaches target host mechanisms, the risk of resistance

development is substantially lower than with traditional antibiotics. Although still in the early stages of development, host-directed therapies may become valuable components of future treatment regimens for resistant *K. pneumoniae* infections.

Table 4. Emerging Therapeutic Strategies Against Antimicrobial-Resistant Klebsiella pneumoniae

Strategy	Primary Mechanism	Major Advantages	Current Development Stage
Novel Antibiotics	Inhibition of resistant bacteria	Effective against MDR strains	Clinical use
Antimicrobial Peptides	Membrane disruption	Broad-spectrum activity	Clinical trials
Bacteriophage Therapy	Bacterial lysis	High specificity	Experimental
Immunotherapy	Host immune enhancement	Reduced resistance pressure	Clinical development
Nanotechnology	Enhanced drug delivery	Improved biofilm penetration	Experimental
CRISPR-Cas Systems	Gene editing	Precision targeting	Research stage
Anti-Biofilm Strategies	Biofilm disruption	Enhanced antibiotic efficacy	Experimental
Host-Directed Therapies	Immune modulation	Reduced resistance risk	Early development

6. Infection Prevention and Control Strategies

The prevention and control of antimicrobial- resistant *Klebsiella pneumoniae* infections are essential components of global efforts to combat antimicrobial resistance (AMR). While the development of novel therapeutic agents remains important, preventing the emergence and transmission of resistant strains is considerably more effective and cost-efficient than treating established infections. Healthcare-associated transmission continues to be the primary route for the dissemination of multidrug-resistant (MDR) and carbapenem-resistant *K. pneumoniae* (CRKP), particularly in intensive care units (ICUs), long-term care facilities, and other high-risk healthcare environments.

Strict adherence to infection prevention and control (IPC) measures represents the first line of defense against resistant *K. pneumoniae*. Hand hygiene remains the single most effective intervention for reducing pathogen transmission within healthcare settings. Proper handwashing and alcohol-based hand rubs significantly decrease the risk of cross-contamination between patients, healthcare workers, and contaminated surfaces.

Active surveillance programs are equally important for the early identification of colonized or infected patients. Routine screening of high-risk individuals, particularly those admitted to ICUs or transferred from healthcare facilities with known outbreaks, enables timely implementation of containment measures. Once identified, colonized or infected patients should be isolated or cohorted to minimize transmission.

Environmental contamination plays a crucial role in the persistence and spread of *K. pneumoniae*. The organism can survive for prolonged periods on medical equipment, hospital furniture, and environmental surfaces. Therefore, regular cleaning, disinfection, and sterilization of medical devices and patient-care areas are essential components of infection control programs.

Antimicrobial stewardship programs (ASPs) have become indispensable in reducing selective pressure associated with inappropriate antibiotic use. These programs promote evidence-based prescribing practices, optimize antibiotic selection and duration, and minimize unnecessary exposure to broad- spectrum agents. Effective stewardship has been associated with reductions in resistance rates, healthcare costs, and infection-related mortality.

Education and training of healthcare personnel are also critical for successful infection control. Continuous professional development programs improve compliance with IPC guidelines and enhance awareness regarding AMR risks. Additionally, molecular surveillance and genomic epidemiology can facilitate outbreak investigations and support targeted interventions.

A comprehensive infection prevention strategy integrating surveillance, stewardship, environmental hygiene, patient isolation, and healthcare worker education is essential to limit the spread of antimicrobial-resistant *K. pneumoniae* and preserve the effectiveness of existing therapeutic options.

Table 5. Infection Prevention and Control Measures Against Antimicrobial-Resistant Klebsiella pneumoniae

Control Measure	Objective	Expected Outcome
Hand Hygiene	Prevent person-to-person transmission	Reduced infection rates
Active Surveillance	Early detection of carriers	Rapid containment
Patient Isolation	Limit spread within healthcare facilities	Reduced outbreaks
Environmental Cleaning	Eliminate environmental reservoirs	Lower contamination levels
Antimicrobial Stewardship	Rational antibiotic use	Reduced resistance emergence
Healthcare Worker Training	Improve compliance with IPC protocols	Enhanced infection control
Molecular Surveillance	Track resistant clones	Improved outbreak management

7. Future Research Directions

Despite significant advances in understanding antimicrobial resistance mechanisms and therapeutic interventions, *Klebsiella pneumoniae* continues to pose a substantial threat to global public health. Future research should focus on developing innovative and sustainable solutions capable of addressing both existing and emerging resistance challenges.

One of the most important priorities is the discovery of novel antimicrobial compounds with unique mechanisms of action. Traditional antibiotic discovery pipelines have slowed considerably, making alternative approaches such as artificial intelligence-assisted drug discovery, computational screening, and genome-guided target identification increasingly valuable. These technologies may accelerate the identification of new drug candidates capable of overcoming current resistance mechanisms.

The development of precision medicine approaches represents another promising research area. Advances in whole-genome sequencing, metagenomics, transcriptomics, and proteomics can facilitate personalized antimicrobial therapy based on pathogen-specific resistance profiles. Such approaches may improve treatment outcomes while minimizing unnecessary antibiotic exposure.

Further investigation into bacteriophage therapy is also warranted. Although encouraging results have

been reported in experimental and compassionate- use settings, large-scale clinical trials are required to establish efficacy, safety, and standardized treatment protocols. Similarly, optimization of antimicrobial peptides, nanoparticle-based therapeutics, and anti-biofilm agents may generate effective alternatives to conventional antibiotics.

Gene-editing technologies such as CRISPR-Cas systems offer unprecedented opportunities for selectively eliminating resistance genes. Future studies should focus on improving delivery systems, enhancing targeting specificity, and evaluating long- term safety in clinical settings. Likewise, vaccine development remains a priority, particularly for high-risk populations vulnerable to healthcare- associated infections.

Host-directed therapies and microbiome-based interventions are emerging as innovative approaches that may reduce selective pressure for resistance while enhancing host immunity. Understanding host-pathogen interactions at the molecular level will be essential for the successful development of these strategies.

Finally, international collaboration and global surveillance networks must be strengthened to monitor emerging resistance patterns, identify high- risk clones, and support coordinated public health responses. Integrating advanced technologies with multidisciplinary research efforts will be critical for addressing the evolving threat posed by antimicrobial-resistant *K. pneumoniae*.

8. Conclusion

Antimicrobial resistance in *Klebsiella pneumoniae* has emerged as one of the most serious challenges confronting modern medicine. The pathogen possesses a remarkable capacity to acquire and disseminate resistance determinants through multiple mechanisms, including β-lactamase production, biofilm formation, efflux pump overexpression, enzymatic antibiotic modification, reduced membrane permeability, and horizontal gene transfer. These mechanisms have facilitated the global spread of multidrug-resistant and carbapenem-resistant strains, significantly limiting available treatment options and increasing healthcare burdens worldwide.

Although current therapeutic agents such as polymyxins, tigecycline, fosfomycin, and novel β- lactam/β-lactamase inhibitor combinations provide important treatment alternatives, the continued emergence of resistance highlights the limitations of conventional antimicrobial therapy. Consequently, innovative approaches including antimicrobial peptides, bacteriophage therapy, immunotherapy, nanotechnology-based therapeutics, CRISPR-Cas gene-editing systems, anti-biofilm strategies, and host-directed therapies have gained considerable attention as potential solutions.

In addition to therapeutic innovation, effective infection prevention and control measures remain fundamental for limiting the spread of resistant strains. Antimicrobial stewardship programs, active surveillance, environmental hygiene, patient isolation, and healthcare worker education collectively play a crucial role in reducing transmission and preserving the effectiveness of existing antibiotics.

The future management of antimicrobial-resistant *K. pneumoniae* will require a multidisciplinary approach that integrates novel therapeutic technologies, precision medicine, advanced diagnostics, and global surveillance initiatives. Continued investment in scientific research, healthcare infrastructure, and international collaboration is essential to combat this increasingly resistant pathogen. By combining innovative treatment strategies with robust prevention

measures, it may be possible to reduce the global burden of *K. pneumoniae* infections and safeguard the effectiveness of antimicrobial therapies for future generations.

References

1. Bengoechea, J. A., & Pessoa, J. S. (2019). Klebsiella pneumoniae infection biology: Living to counteract host defences. *FEMS Microbiology Reviews, 43*(2), 123–144. https://doi.org/10.1093/femsre/fuy043
2. Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., Johnson, S. C., Browne, A. J., Chipeta, M. G., Fell, F., Hackett, S., Haines-Woodhouse, G., Kashef Hamadani, B. H., Kumaran, E. A. P., McManigal, B., ... Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet, 399*(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
3. Navon-Venezia, S., Kondratyeva, K., & Carattoli, A. (2017). Klebsiella pneumoniae: A major worldwide source and shuttle for antibiotic resistance. *FEMS Microbiology Reviews, 41*(3), 252–275. https://doi.org/10.1093/femsre/fux013
4. Rodríguez-Martínez, J. M., Díaz de Alba, P., Briales, A., Machuca, J., Lossa, M., Fernández- Cuenca, F., Rodríguez-Baño, J., Martínez- Martínez, L., & Pascual, A. (2013). Contribution of OqxAB efflux pumps to quinolone resistance in extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae. *Journal of Antimicrobial Chemotherapy, 68*(1), 68–73. https://doi.org/10.1093/jac/dks377
5. Wong, M. H. Y., Chan, E. W. C., & Chen, S. (2015). Evolution and dissemination of OqxAB- like efflux pumps. *Antimicrobial Agents and Chemotherapy, 59*(6), 3290–3297. https://doi.org/10.1128/AAC.00310-15
6. Li, J., Zhang, H., Ning, J., Sajid, A., Cheng, G., Yuan, Z., Hao, H., & Pan, Y. (2019). The nature and epidemiology of OqxAB. *Antimicrobial Resistance & Infection Control, 8*(1), 44. https://doi.org/10.1186/s13756-019-0489-3
7. Vuotto, C., Longo, F., Balice, M. P., Donelli, G., & Varaldo, P. E. (2014). Antibiotic resistance related to biofilm formation in Klebsiella pneumoniae. *Pathogens, 3*(3), 743–758. https://doi.org/10.3390/pathogens3030743
8. Flemming, H. C., Wingender, J., Szewzyk, U., Steinberg, P., Rice, S. A., & Kjelleberg, S. (2016). Biofilms: An emergent form of bacterial life. *Nature Reviews Microbiology, 14*(9), 563–575. https://doi.org/10.1038/nrmicro.2016.94
9. Ramirez, M. S., & Tolmasky, M. E. (2010). Aminoglycoside modifying enzymes. *Drug Resistance Updates, 13*(6), 151–171. https://doi.org/10.1016/j.drup.2010.08.003
10. Schaenzer, A. J., & Wright, G. D. (2020). Antibiotic resistance by enzymatic modification of antibiotic targets. *Trends in Molecular Medicine, 26*(8), 768–782. https://doi.org/10.1016/j.molmed.2020.05.004
11. Bevan, E. R., Jones, A. M., & Hawkey, P. M. (2017). Global epidemiology of CTX-M β- lactamases. *Journal of Antimicrobial Chemotherapy, 72*(8), 2145–2155. https://doi.org/10.1093/jac/dkx146
12. Liao, W., Liu, Y., & Zhang, W. (2020). Virulence evolution, molecular mechanisms of resistance and prevalence of ST11 carbapenem-resistant Klebsiella pneumoniae in China. *Journal of Global Antimicrobial Resistance, 23*, 174–180. https://doi.org/10.1016/j.jgar.2020.09.004
13. Bai, J., Zhang, F., Liang, S., et al. (2022). Isolation and characterization of vB_kpnM_17- 11, a novel phage efficient against carbapenem-

resistant Klebsiella pneumoniae. *Frontiers in Cellular and Infection Microbiology, 12*, 897531. https://doi.org/10.3389/fcimb.2022.897531

14. Gan, L., Fu, H., Tian, Z., et al. (2022). Bacteriophage effectively rescues pneumonia caused by multidrug-resistant Klebsiella pneumoniae. *Microbiology Spectrum, 10*(5), e02358-22. https://doi.org/10.1128/spectrum.02358-22
15. Molchanova, N., Hansen, P. R., & Franzyk, H. (2017). Advances in development of antimicrobial peptidomimetics as potential drugs. *Molecules, 22*(9), 1430. https://doi.org/10.3390/molecules22091430
16. Olekson, M. A., You, T., Savage, P. B., & Leung, K. P. (2017). Antimicrobial ceragenins inhibit biofilms. *FEBS Open Bio, 7*(7), 953–967. https://doi.org/10.1002/2211-5463.12235
17. Lee, C. R., Lee, J. H., Park, K. S., et al. (2016). Global dissemination of carbapenemase- producing Klebsiella pneumoniae. *Frontiers in Microbiology, 7*, 895. https://doi.org/10.3389/fmicb.2016.00895
18. Sheu, C. C., Chang, Y. T., Lin, S. Y., Chen, Y. H., & Hsueh, P. R. (2019). Infections caused by carbapenem-resistant Enterobacteriaceae. *Frontiers in Microbiology, 10*, 80. https://doi.org/10.3389/fmicb.2019.00080
19. Abdelraouf, K., Chavda, K. D., Satlin, M. J., Jenkins, S. G., Kreiswirth, B. N., & Nicolau, D. P. (2020). Piperacillin-tazobactam-resistant Escherichia coli and Klebsiella pneumoniae isolates. *International Journal of Antimicrobial Agents, 55*(3), 105885. https://doi.org/10.1016/j.ijantimicag.2020.10 58 85
20. Hamzaoui, Z., Ocampo-Sosa, A., Maamar, E., et al. (2018). An outbreak of NDM-1-producing Klebsiella pneumoniae associated with OmpK35 and OmpK36 porin loss. *Microbial Drug Resistance, 24*(8), 1137–1147. https://doi.org/10.1089/mdr.2017.0386
21. Vergalli, J., Bodrenko, I. V., Masi, M., Moynié, L., Acosta-Gutiérrez, S., Naismith, J. H., Davin- Regli, A., Ceccarelli, M., Van den Berg, B., Winterhalter, M., & Pagès, J. M. (2020). Porins and small-molecule translocation across the outer membrane of Gram-negative bacteria. *Nature Reviews Microbiology, 18*(3), 164–176. https://doi.org/10.1038/s41579-019-0294-2
22. Janek, D., Zipperer, A., Kulik, A., Krismer, B., Peschel, A., & Weidenmaier, C. (2016). High frequency and diversity of antimicrobial activities produced by human commensal bacteria. *Nature, 535*(7613), 511–516. https://doi.org/10.1038/nature18634
23. Kallifidas, D., Kang, H. S., & Brady, S. F. (2012). Tetarimycin A, an MRSA-active antibiotic. *Journal of the American Chemical Society, 134*(48), 19552–19555. https://doi.org/10.1021/ja3093828
24. Chiu, S. K., Chan, M. C., Huang, L. Y., Lin, Y. T., Lin, J. C., Lu, P. L., & Siu, L. K. (2017). Tigecycline resistance among carbapenem- resistant Klebsiella pneumoniae. *PLoS One, 12*(4), e0175140. https://doi.org/10.1371/journal.pone.0175140
25. Lv, F., Cai, J., He, Q., Wang, W., & Luo, W. (2021). Overexpression of efflux pumps mediate pan resistance of Klebsiella pneumoniae sequence type 11. *Microbial Drug Resistance, 27*(10), 1405–1411. https://doi.org/10.1089/mdr.2020.0395
26. Zhong, X., Xu, H., Chen, D., Zhou, H., Hu, X., & Cheng, G. (2014). Emergence of AcrAB- mediated tigecycline resistance. *PLoS One, 9*(12), e115185. https://doi.org/10.1371/journal.pone.0115185

27. Savov, E., Todorova, I., Politi, L., Trifonova, A., & Borisova, M. (2017). Colistin resistance in KPC-2-producing Klebsiella pneumoniae. *Chemotherapy, 62*(6), 339–342. https://doi.org/10.1159/000464275
28. Omeershffudin, U. N. M., & Kumar, S. (2022). Antimicrobial resistance in Klebsiella pneumoniae: Identification of DNA adenine methyltransferase as a novel drug target. *Genomics & Informatics, 20*(4), e47. https://doi.org/10.5808/gi.22067
29. Darboe, S., Carvalheiro, C. G., Haller, S., & Roca, A. (2022). Global burden of antimicrobial resistance. *The Lancet, 399*(10325), 629–655. https://doi.org/10.1016/S0140-6736(21)02724-0
30. Li, Y., Kumar, S., Zhang, L., Wu, H., & Wu, H. (2023). Characteristics of antibiotic resistance mechanisms and genes of Klebsiella pneumoniae. *Open Medicine, 18*(1), 20230707. https://doi.org/10.1515/med-2023-0707